leadf
logo-loader
viewParadigm Biopharmaceuticals Ltd
(
ASX:PAR
)

Paradigm Biopharmaceuticals' pre-clinical food study in chronic heart failure continues ahead of commentary in Q4

Snapshot

  • Paradigm Biopharmaceuticals has study supporting arthritic disease modifying effects of PPS in chikungunya virus published in peer-reviewed journal
  • Paradigm Biopharmaceuticals in new collaboration with bene pharmaChem to co-fund new projects to unlock potential of injectable PPS
  • Paradigm Biopharmaceuticals secures first revenues for Zilosul
Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals lays out roadmap for the future at JP Morgan Healthcare Conference

Quick facts: Paradigm Biopharmaceuticals Ltd

Follow
ASX:PAR

Price: 2.03 AUD

Market Cap: $466.71 m

About the company

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development.

The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application.

Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).

How it is doing

13 Sep 2021

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has highlighted the online publication of a preclinical study investigating the anti-inflammatory and arthritic disease-modifying effects of pentosan polysulfate sodium (PPS) in the mouse model of the alphavirus chikungunga (CHIKV) induced arthralgia in scientific peer-review journal, PLoS ONE. 

The demonstration that PPS can improve strength, swelling and inflammation in the CHIKV preclinical model supports further clinical evaluation of PPS as a potential disease-modifying therapy for CHIKV-induced arthralgia.

This comes on the back of promising clinical outcomes of improved pain and function in subjects in Paradigm’s Phase 2A Ross River virus (RRV) pilot clinical trial. 

The study 'Pentosan polysulfate sodium prevents functional decline in chikungunya infected mice by modulating growth factor signalling and lymphocyte activation' was undertaken at Griffith University’s, Institute for Glycomics by principal investigator and corresponding author of the publication, Dr Lara Herrero. 

27 Aug 2021

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has tabled its FY21 report, reflecting on regulatory and commercial achievements as it works to develop an analgesic for the most common form of arthritis.

The health stock, which is focused on commercially repurposing drugs in a new, patented therapeutic application, is working to translate a historic candidate known as pentosan polysulfate sodium (PPS) or Zilosul® into a treatment for osteoarthritis pain.

06 Aug 2021

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has delivered its June quarter activities report recording additional new avenues for Zilosul® and several other programs in the pipeline.

The highlight of the quarter was the first revenue generated by Paradigm for the provision of Zilosul® to prescribing physicians under the therapeutic goods administration (TGA) special access scheme (SAS).

Insight: Paradigm Biopharmaceuticals in new collaboration with bene pharmaChem to...

31 Mar 2021

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has executed a new collaboration agreement with bene pharmaChem which allows for the further development of injectable Pentosan Polysulfate Sodium (iPPS) and other formulations containing PPS to address unmet needs in new clinical indications. 

Under the new agreement, both parties have agreed to jointly fund the R&D and work collaboratively on new Intellectual Property (IP) creation, which Paradigm will commercialise. 

What management says

20 May 2021

Paradigm Biopharmaceuticals Ltd's (ASX:PAR) (OTCMKTS:PBIGF) Dr Jeannie Joughin tells Proactive's Andrew Scott they've received first revenue through physician prescription of Zilosul® to patients via the Therapeutic Goods Administration (TGA) pay-for-use Special Access Scheme (SAS). Under the SAS, Zilosul® has been made available to physicians with SAS approval to treat patients experiencing chronic arthralgia from Ross River Virus (RRV) infection, previous SAS participants seeking re-treatment and other subjects that would not qualify for recruitment into the Para_OA_008 or Para_OA_002 clinical trials.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Paradigm Biopharmaceuticals secures first revenues for Zilosul

Paradigm Biopharmaceuticals Ltd's (ASX:PAR) (OTCMKTS:PBIGF) Dr Jeannie Joughin tells Proactive's Andrew Scott they've received first revenue through physician prescription of Zilosul® to patients via the Therapeutic Goods Administration (TGA) pay-for-use Special Access Scheme (SAS). Under the...

on 20/5/21

4 min read